Shitara, K., Shen, L., Lee, J., Hoff, P. M., Smyth, E. C., Barrios, D., Kobayashi, K., Okuda, Y., Kamio, T., Janjigian, Y. Y. (2026). An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps468